ABOUT US
Nativus Group unites companies working in the field of novel medicinal and therapeutic compound research, development, production and marketing.
We are NATIVUS
We are a group of companies dedicated to the advancement of pharmaceutical, wellness and cosmetics industries.
OUR WORK
Our work is focused on natural compounds found in plants that are finally regaining the well-deserved attention.
WE UNDERSTAND THE POTENTIAL
These compounds are only now coming into the spotlight and an overwhelming amount of scientific research indicates their vast potential to treat a number of the most pressing physical and mental ailments, including, among others, depression, anxiety, sleeplessness, pain and inflammation.
Group
Neurostrain is a biotechnology company developing naturally occurring active compounds intended for treatment of neurological ailments.
Nativus Trade markets and sells products developed and produced by Sanobiotec and Neurostrain. It is also developing an online sales and…
Sanobiotec is the research and development company of Nativus Group that identifies, develops and produces cannabinoids and flavonoids.
News & Media
Minor cannabinoid could “revolutionise” autism medication
Out of more than a hundred cannabinoids that have so far been identified in the cannabis sativa plant, the non-intoxicating cannabidivarin (CBDV) shows unique promise in fulfilling unmet needs in the treatment for autism spectrum disorders (ASD). Following successful pre-clinical studies in mouse models and demonstration of therapeutic effect in repetitive behaviours, irritability, social functioning, inflammation, and quality of life, CBDV is now being examined for safety and efficacy using an interventional Phase 2 study in children with ASD. “In addition to its anti-seizure and anti-epileptic properties, CBDV has also successfully demonstrated little to no effect on weight and metabolism, which are the primary complications associated with existing ASD therapeutics,” explained Rytis V. Urbonas, CEO at Sanobiotec. These promising results come on the heels of the FDA’s decision to grant CBDV ‘orphan designation’ in the treatment of Fragile X and Rett syndromes. CBDV was shown to decrease motor impairments and cognitive decline in mouse models of Rett syndrome. Furthermore, the positive effects of CBDV lasted up to 2 weeks after administration. Since the symptoms of Rett Syndrome overlap with ASD, scientists began to explore the effect of CBDV mediated neurochemical signaling on symptoms of ASD. “Currently 1 in 160 children have been identified with deficits in social and cognitive functioning characteristic of ASD […]... read more →
2020-11-07
Firm creates rare cannabinoid used in chronic disease treatment
It is hoped that the pure ingredient will open up new research prospects for pharma, wellness industry, and other market players.
... read more →
2020-10-29
Exploring nuances of cannabinoid bioavailability: how water-soluble products can lead to greater absorption
The question of how to achieve greater bioavailability of cannabinoids has been one of the main challenges for researchers in the cannabis industry, and for a good reason.... read more →
2020-08-20
Biotechnology | Go Vilnius
If you check out the biotechnology sector overview on Go Vilnius website, you might notice a familiar name – #Sanobiotec among fellow biotech companies operating from Vilnius. ... read more →
2020-05-25
Sanobiotec taps into potential of minor cannabinoids
Sanobiotec aims to improve the technological processes for production of these compounds and leverage their therapeutic benefits for pharmaceuticals, wellness industry and treatment of progressive illnesses, such as cancer or Alzheimer’s.... read more →
2020-05-22
Deepening the search for cannabis plant’s best kept secrets
The cannabinoids THC and CBD are the most prominent compounds in the cannabis industry and are well-known for their health benefits.... read more →
2020-05-17